ProPhase Continues its Exploration of a Crypto Treasury Strategy
ProPhase Labs (NASDAQ: PRPH) announced its continued exploration of a crypto treasury strategy following stockholder approval at the September 9 Special Meeting. The company has entered into an agreement for potential advisory services to evaluate balance sheet resource allocation options, including digital asset investments.
CEO Ted Karkus highlighted that the company recently cancelled its Equity Line of Credit (ELOC) to avoid dilutive financing, citing significant underlying company value. Additionally, ProPhase anticipates updates on its Crown Medical Collections initiatives, which could generate $50 million in cash, and developments in its BE-Smart™ Esophageal cancer test.
ProPhase Labs (NASDAQ: PRPH) ha annunciato la continua esplorazione di una strategia di tesoreria in criptovalute, dopo l'approvazione degli azionisti alla riunione speciale del 9 settembre. L'azienda ha stipulato un accordo per potenziali servizi di consulenza per valutare opzioni di allocazione delle risorse di bilancio, inclusi investimenti in asset digitali. Il CEO Ted Karkus ha sottolineato che recentemente è stata annullata la Linea di Credito Azionaria (ELOC) per evitare finanziamenti diluitivi, citando un significativo valore sottostante dell'azienda. Inoltre, ProPhase prevede aggiornamenti sulle sue iniziative Crown Medical Collections, che potrebbero generare fino a 50 milioni di dollari in contanti, e sviluppi nel test BE-Smart™ per il cancro esofageo.
ProPhase Labs (NASDAQ: PRPH) anunció su continua exploración de una estrategia de tesorería con criptomonedas tras la aprobación de los accionistas en la Reunión Especial del 9 de septiembre. La empresa ha suscrito un acuerdo para posibles servicios de asesoría para evaluar opciones de asignación de recursos en el balance, incluidas inversiones en activos digitales. El CEO Ted Karkus destacó que recientemente cancelaron su Línea de Crédito de Capital (ELOC) para evitar financiamiento dilutivo, citando un valor subyacente significativo de la empresa. Además, ProPhase anticipa actualizaciones sobre sus iniciativas Crown Medical Collections, que podrían generar hasta 50 millones de dólares en efectivo, y desarrollos en su prueba BE-Smart™ para el cáncer de esófago.
ProPhase Labs(NASDAQ: PRPH)는 9월 9일의 특별 주주총회에서 주주들의 승인을 받은 후 암호화폐 자금 전략에 대한 지속적인 탐색을 발표했다. 회사는 디지털 자산 투자 포함, 대차대조표 자원 배분 옵션을 평가하기 위한 잠재적 자문 서비스 계약을 체결했다. CEO Ted Karkus는 주식 희석 자금을 피하기 위해 최근 주식담보신용대출(ELOC)을 취소했다고 강조하며, 회사의 상당한 기초 가치에 주목했다. 또한 ProPhase는 Crown Medical Collections 이니셔티브가 현금으로 5천만 달러를 창출할 수 있다는 가능성과 BE-Smart™ 식도암 검사의 개발에 대한 업데이트를 기대한다고 밝혔다.
ProPhase Labs (NASDAQ : PRPH) a annoncé la poursuite de l’exploration d’une stratégie de trésorerie crypto après l’approbation des actionnaires lors de la réunion spéciale du 9 septembre. L’entreprise a conclu un accord pour d’éventuels services de conseil afin d’évaluer les options d’allocation des ressources du bilan, y compris les investissements dans des actifs numériques. Le PDG Ted Karkus a souligné que l’entreprise a récemment annulé sa ligne de crédit sur actions (ELOC) pour éviter un financement dilutif, citant une valeur sous-jacente importante. De plus, ProPhase prévoit des mises à jour sur ses initiatives Crown Medical Collections, qui pourraient générer jusqu’à 50 millions de dollars en liquidités, et les développements dans son test BE-Smart™ pour le cancer de l’œsophage.
ProPhase Labs (NASDAQ: PRPH) kündigte die fortgesetzte Prüfung einer Krypto-Tresor-Strategie an, nachdem die Aktionäre bei der Sonderversammlung am 9. September zugestimmt hatten. Das Unternehmen hat eine Vereinbarung für potenzielle Beratungsdienstleistungen abgeschlossen, um Optionen zur Ressourcenallokation in der Bilanz zu bewerten, einschließlich Investitionen in digitale Vermögenswerte. CEO Ted Karkus hob hervor, dass das Unternehmen kürzlich seine Equity Line of Credit (ELOC) storniert hat, um verwässernde Finanzierung zu vermeiden, und verwies auf den erheblichen darunterliegenden Unternehmenswert. Zudem rechnet ProPhase mit Updates zu seinen Crown Medical Collections-Initiativen, die bis zu 50 Millionen Dollar an Bargeld bringen könnten, und Entwicklungen in seinem BE-Smart™-Ösophagus-Krebs-Test.
أعلنت ProPhase Labs (ناسداك: PRPH) عن استمرار استكشافها لاستراتيجية خزانة تشفير عقب موافقة المساهمين في الاجتماع الخاص بتاريخ 9 سبتمبر. دخلت الشركة في اتفاق لخدمات استشارية محتملة لتقييم خيارات تخصيص موارد الميزانية، بما في ذلك الاستثمارات في الأصول الرقمية. أكد الرئيس التنفيذي تيد كاركاس أن الشركة ألغت مؤخرًا خط ائتمان الأسهم (ELOC) لتفادي التمويل المِحصور، مشيرًا إلى قيمة أساسية كبيرة للشركة. بالإضافة إلى ذلك، تتوقع ProPhase تحديثات بشأن مبادرات Crown Medical Collections، التي قد تولد حتى 50 مليون دولار نقداً، وتطورات في اختبارها BE-Smart™ لسرطان المريء.
ProPhase Labs（纳斯达克代码：PRPH）宣布在9月9日特别股东大会通过后，继续探索加密货币财政策略。公司已就评估资产负债表资源分配选项（包括数字资产投资）签署潜在咨询服务的协议。CEO Ted Karkus 指出，为避免稀释性融资，公司最近取消了其股权信用额度（ELOC），并指出公司潜在价值显著。此外，ProPhase 预计在其 Crown Medical Collections 项目， 可能带来5000万美元现金，以及其 BE-Smart™ 食管癌检测的进展。
- Potential $50 million cash inflow from Crown Medical Collections initiatives
- Stockholder approval received for crypto treasury strategy
- Cancellation of ELOC prevents shareholder dilution
- Progress in BE-Smart™ Esophageal cancer test development
- Uncertainty around implementation of crypto treasury strategy
- Potential risks associated with digital asset investments
- Crown Medical Collections cash generation not yet secured
UNIONDALE, NY, Sept. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that the Company entered into an agreement relating to potential advisory services. Management continues to evaluate a range of options for potential allocation of balance sheet resources, including the possibility of investing in digital assets.
“Following our stockholders’ approval of all proxy items at the September 9 Special Meeting, ProPhase is now positioned to advance its crypto treasury strategy,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “We believe that we have significant underlying value in the Company, potentially multiples of the current market capitalization. Therefore, we have no interest in a discounted, dilutive round of financing. In fact, the Company recently cancelled its ELOC (Equity Line of Credit) for just this reasoning.”
Mr. Karkus continued, “To the contrary, we are working on a crypto treasury strategy with a goal that it will be structured to be accretive to current shareholders given the significant underlying value of the Company’s assets. Furthermore, very shortly, we anticipate updating our shareholders on our Crown Medical Collections initiatives that could net
The Company is committed to continued transparency and committed to making efforts to preserve and grow value for its shareholders.
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Details about these risks and uncertainties can be found in our filings with the SEC. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
FAQ
What is ProPhase Labs' (PRPH) new crypto treasury strategy?
How much cash could ProPhase Labs generate from Crown Medical Collections?
Why did ProPhase Labs cancel its Equity Line of Credit (ELOC)?
What developments are expected in ProPhase Labs' cancer testing business?
How will ProPhase Labs' crypto strategy affect shareholders?
